Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Smith & Nephew Snats ( (SNN) ) has shared an announcement.
Smith & Nephew reported strong financial results for the fourth quarter and full year of 2024, driven by its transformative 12-Point Plan. The company achieved higher revenue growth, margin expansion, and strong cash flow, with significant contributions from new product launches. Despite challenges such as inflation and headwinds in China, the company improved its operating profit and cash generation, and expects further performance improvements in 2025.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company that focuses on developing advanced medical devices. The company is known for its innovative products in areas such as orthopedics, sports medicine, and wound management, with a strong market presence in the healthcare industry.
YTD Price Performance: 7.70%
Average Trading Volume: 750,917
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.49B
Learn more about SNN stock on TipRanks’ Stock Analysis page.